

## Review Article

*Drug Therapy*ALASTAIR J.J. WOOD, M.D., *Editor*

## DRUGS IN PREGNANCY

GIDEON KOREN, M.D., ANNE PASTUSZAK, M.Sc.,  
AND SHINYA ITO, M.D.

**B**EFORE marketing a new drug, the manufacturer almost never tests the product in pregnant women to determine its effects on the fetus. Consequently, most drugs are not labeled for use during pregnancy. Typically, descriptions of drugs that appear in the *Physicians' Desk Reference* and similar sources contain statements such as, "Use in pregnancy is not recommended unless the potential benefits justify the potential risks to the fetus." Since the risk has been adequately established for only a few drugs, physicians caring for pregnant women have very little information to help them decide whether the potential benefits to the mother outweigh the risks to the fetus. These typical disclaimers, although understandable from the medicolegal standpoint, put large numbers of women and their physicians in difficult situations for several reasons. One is that at least half the pregnancies in North America are unplanned,<sup>1</sup> and every year, hundreds of thousands of women therefore expose their fetuses to drugs before they know they are pregnant. Such women often interpret the statement that use during pregnancy is not recommended as meaning that the drug is not safe during pregnancy. There is evidence that this perception of fetal risk causes many women to consider or even seek termination of otherwise wanted pregnancies.<sup>2,3</sup> Another reason is that with the recent increase in the age at which women have children, conditions that necessitate long-term drug therapy are diagnosed in larger numbers of women

before pregnancy. Furthermore, for pregnant women with certain conditions once believed to be incompatible with pregnancy, such as systemic lupus erythematosus and heart diseases, the outcome of pregnancy has improved dramatically in the past few decades.<sup>4</sup>

In this article, we review current knowledge of the fetal and neonatal effects of prescription and over-the-counter drugs given to pregnant women, with an emphasis on the approaches used to determine safety and risk. In addition, we review approaches to communicating such information to pregnant women and their families.

## HUMAN TERATOGENESIS

Teratogenesis is defined as the dysgenesis of fetal organs as evidenced either structurally or functionally (e.g., brain functions).<sup>5</sup> The typical manifestations of teratogenesis are restricted growth or death of the fetus, carcinogenesis, and malformations,<sup>6</sup> defined as defects in organ structure or function. These abnormalities vary in severity (e.g., hypospadias that is mild and may be missed, or is severe, necessitating several corrective operations). Major malformations may be life-threatening and require major surgery or may have serious cosmetic or functional effects.

## A HISTORICAL PERSPECTIVE

Several milestones highlight the problems of drug therapy facing pregnant women, their families, and health professionals.

**Thalidomide**

For decades it was believed that the placenta served as a barrier that protected the fetus from the adverse effects of drugs. The thalidomide disaster drastically changed this perception by demonstrating that fetal exposure to the drug during critical periods of development resulted in severe limb defects and other organ dysgenesis (e.g., kidney and heart defects).<sup>6,7</sup> Despite the high rates of malformations (20 to 30 percent) and their characteristic pattern, the teratogenicity of thalidomide was not suspected for years. The suffering it caused has prompted the belief that every drug has the potential to be a new thalidomide.<sup>2,3</sup>

Most known human teratogens are associated with much lower rates of malformations, and the syndromes they cause are not always so pathognomonic, making causation more difficult to confirm. Yet 35 years after the recognition of thalidomide-associated embryopathy, fewer than 30 drugs have been proved to be teratogenic in humans when used

From the Motherisk Program, Division of Clinical Pharmacology and Toxicology (G.K., A.P., S.I.), the Departments of Pediatrics and Population Health Sciences (G.K., S.I.), and the Research Institute (G.K., S.I.), Hospital for Sick Children; and the Departments of Pediatrics (G.K., S.I.), Pharmacology (G.K., S.I.), and Medicine (G.K.), University of Toronto — both in Toronto. Address reprint requests to Dr. Koren at the Division of Clinical Pharmacology, Hospital for Sick Children, 555 University Ave., Toronto, ON M5G 1X8, Canada.

©1998, Massachusetts Medical Society.

in clinically effective doses, and even fewer are currently in clinical use (Table 1). Many other commonly used drugs, including salicylates, glucocorticoids, and spermicides, were once thought to be teratogenic but have been shown to be safe in subsequent studies that were larger and better controlled than the initial studies (Table 2).

**Bendectin**

One example of the gap between the perception of teratogenic risk and evidence-based proof of safety is the case of Bendectin. During the late 1950s and the 1960s, this drug, a combination of an antihistamine (doxylamine) and pyridoxine, was the most widely used medication in the United States for nausea and vomiting associated with pregnancy. During the 1970s, many lawsuits claiming that Bendectin was teratogenic were filed against the manufacturer in American courts. Therefore, the drug was withdrawn from the market by its manufacturer in 1982, which left millions of pregnant women without a drug approved by the Food and Drug Administra-

tion (FDA) for the treatment of nausea and vomiting. The rate of hospitalization for severe nausea and vomiting during pregnancy increased by a factor of 2 in both the United States and Canada after Bendectin was withdrawn from the market (Fig. 1).

The drug was withdrawn despite a substantial body of evidence that the rate of major malformations among the children of women who had received Bendectin during pregnancy did not differ from the rate in the general population.<sup>24,25</sup> Withdrawal of the drug from the American market did not decrease the rate of any specific category of malformation, as would be expected for a truly teratogenic drug estimated to have been used by up to 40 percent of pregnant women at one time.<sup>26,27</sup>

In Canada, the drug continues to be marketed under the trade name Diclectin. A review committee has advised the Canadian Minister of Health that the drug is safe.<sup>27</sup> A recent study revealed that severe nausea and vomiting of pregnancy often lead women to terminate or consider the termination of otherwise wanted pregnancies.<sup>28</sup> Other formulations of dox-

**TABLE 1. DRUGS WITH PROVEN TERATOGENIC EFFECTS IN HUMANS.\***

DRUG	TERATOGENIC EFFECT
Aminopterin†, methotrexate	CNS and limb malformations
Angiotensin-converting-enzyme inhibitors	Prolonged renal failure in neonates, decreased skull ossification, renal tubular dysgenesis
Anticholinergic drugs	Neonatal meconium ileus
Antithyroid drugs (propylthiouracil and methimazole)	Fetal and neonatal goiter and hypothyroidism, aplasia cutis (with methimazole)
Carbamazepine	Neural-tube defects
Cyclophosphamide	CNS malformations, secondary cancer
Danazol and other androgenic drugs	Masculinization of female fetuses
Diethylstilbestrol†	Vaginal carcinoma and other genitourinary defects in female and male offspring
Hypoglycemic drugs	Neonatal hypoglycemia
Lithium	Ebstein's anomaly
Misoprostol	Moebius sequence
Nonsteroidal antiinflammatory drugs	Constriction of the ductus arteriosus‡, necrotizing enterocolitis
Paramethadione†	Facial and CNS defects
Phenytoin	Growth retardation, CNS deficits
Psychoactive drugs (e.g., barbiturates, opioids, and benzodiazepines)	Neonatal withdrawal syndrome when drug is taken in late pregnancy
Systemic retinoids (isotretinoin and etretinate)	CNS, craniofacial, cardiovascular, and other defects
Tetracycline	Anomalies of teeth and bone
Thalidomide	Limb-shortening defects, internal-organ defects
Trimethadione†	Facial and CNS defects
Valproic acid	Neural-tube defects
Warfarin	Skeletal and CNS defects, Dandy-Walker syndrome

\*Only drugs that are teratogenic when used at clinically recommended doses are listed. The list includes all drugs proved to affect neonatal morphology or brain development and some of the toxic manifestations predicted on the basis of the pharmacologic actions of the drugs. Data are from Briggs et al.<sup>8</sup> CNS denotes central nervous system.

†The drug is not currently in clinical use.

‡Sulindac probably does not have this effect.

**TABLE 2. COMMON DRUGS INITIALLY THOUGHT TO BE TERATOGENIC BUT SUBSEQUENTLY PROVED SAFE.**

DRUG	INITIAL EVIDENCE OF RISK	SUBSEQUENT EVIDENCE OF SAFETY
Diazepam*	Oral clefts <sup>9</sup>	No increase in risk in large cohort and case-control studies <sup>10-12</sup>
Oral contraceptives	Birth defects involving the vertebrae, anus, heart, trachea, esophagus, kidney, and limbs <sup>13</sup> ; masculinizing effects on female fetuses resulting in pseudohermaphroditism <sup>14</sup>	No association between first-trimester exposure to oral contraceptives and malformations in general or external genital malformations in two meta-analyses <sup>15,16</sup>
Spermicides	Limb defects, tumors, Down's syndrome, and hypospadias <sup>17</sup>	No increase in risk in a meta-analysis <sup>18</sup>
Salicylates	Cleft palate <sup>19</sup> and congenital heart disease	No increase in risk in large cohort studies <sup>20,21</sup>
Bendectin (doxylamine plus pyridoxine)	Cardiac and limb defects <sup>22,23</sup>	No increase in risk in two meta-analyses <sup>24,25</sup>

\*Diazepam taken near term may cause the neonatal withdrawal syndrome or cardiorespiratory instability.


ylamine in combination with pyridoxine are available in other countries (e.g., South Africa, Spain, and Thailand).

**Isotretinoin**

The experience with thalidomide led drug regulators, drug manufacturers, and the medical community to believe that appropriate labeling of teratogenic drugs, with warnings not to take them around the time of conception, would be effective in preventing fetal exposure to the drugs. The naiveté of

this belief became evident after isotretinoin was introduced in North America in the early 1980s for the treatment of acne. For years before its clinical introduction, this drug had been known to cause malformations in animals.<sup>29</sup> Despite explicit warning labels, scores of children with retinoid embryopathy were born in the years after the drug was introduced.<sup>30</sup> Such warnings are not sufficient, because women taking isotretinoin may not plan their pregnancies, or their birth-control methods may fail. In addition, some women and men are functionally illiterate, and they may not read or understand the content of a drug label.<sup>31</sup>

The initial experience with isotretinoin led to the development of a more comprehensive program to prevent teratogenesis. The Retinoid Pregnancy Prevention Program includes explicit and detailed printed warnings as well as a line drawing of a malformed child,<sup>32</sup> and as part of the program, women are asked to sign a consent form indicating that they agree to use two effective methods of contraception before therapy is started. Since the program was implemented in 1989, a substantial number of fetuses have been exposed to the drug. As many as 30 percent of the women with exposed fetuses did not use any mode of contraception, even though they were cognizant of the high fetal risk.<sup>32</sup> Many of these women explained that they did not believe they were fertile, since they had not conceived during periods of months or years when they had not used contraceptive methods.<sup>33</sup>



**Figure 1.** Rates of Hospitalization among Pregnant Women with Severe Nausea and Vomiting and Numbers of Prescriptions for Bendectin and Diclectin in North America, 1979 through 1989.

Bendectin was withdrawn from the U.S. market in 1982, whereas Diclectin, the same drug, remained on the market in Canada. Adapted from Neutel and Johansen with the permission of the publisher.<sup>26</sup>

**CURRENT TRENDS IN PREVENTING FETAL EXPOSURE TO TERATOGENS**

The advent of effective injectable hormonal contraceptives has made it possible to minimize the risk of an unplanned pregnancy during therapy with a known teratogen. This approach was first implemented in South America, where sexually active women with cutaneous leprosy were injected with medroxy-

progesterone before receiving a prescription for thalidomide.<sup>34</sup> Yet numerous new cases of thalidomide-associated embryopathy have been reported in the children of women who continued to take the drug after the period of contraceptive efficacy (three months) or who received the drug from their male partners.<sup>34</sup>

Because any new drug may be teratogenic, it is important to develop more effective methods to prevent fetal exposure. One such method may be the use of implantable hormonal compounds (e.g., levonorgestrel implants), which can provide long-term, reversible contraception for up to five years. Levonorgestrel implants have documented efficacy in young women in whom oral methods of contraception are likely to fail.<sup>35</sup> Implants should be considered by sexually active women who are taking a teratogen medicinally (e.g., phenytoin or warfarin) or as part of a pattern of substance abuse (e.g., alcohol or cocaine). Furthermore, women taking teratogenic drugs who are not sexually active should be informed of the availability of effective postcoital contraceptives.<sup>35,36</sup>

#### THE PROCESS OF ESTABLISHING RISK OR SAFETY OF DRUGS IN PREGNANCY

Every year, many new drugs are approved and marketed. By this stage, several thousand people have usually participated in studies of the drugs, but the majority have been men. Since there are scarcely any data on fetal effects at the time of marketing, data from studies in animals provide the initial guidelines.

#### The Value of Studies in Animals

Typically, studies of reproductive toxicology in animals compare the outcome of pregnancy in groups of animals receiving a range of doses of the drug in question during the period of organogenesis with the outcome in untreated (control) animals. The occurrence of thalidomide-associated embryopathy led to the erroneous belief that human teratogenicity could not be predicted on the basis of studies in animals. However, every drug that has since been found to be teratogenic in humans has caused similar teratogenic effects in animals (Table 3), except misoprostol, which causes a morphologic pattern known as the Moebius sequence in humans. In at least one case, that of isotretinoin, the studies in animals probably prevented a disaster similar to that of thalidomide.<sup>29</sup>

However, there are drugs that have teratogenic effects in animals when administered in high doses that are not teratogenic in humans given clinically relevant doses. For example, high doses of glucocorticoids<sup>19,70-75</sup> or benzodiazepines<sup>76,77</sup> can cause oral clefts in animals, but clinically relevant doses in humans have no such effects.<sup>10-12,75</sup> Similarly, sa-

licylates<sup>78-80</sup> cause cardiac malformations in animals but not in humans.<sup>20,21</sup> Such discrepancies have led to unwarranted anxiety on the part of women, their families, and physicians and may have contributed to unnecessary terminations of pregnancies.<sup>3</sup> Although studies in animals may identify teratogenic effects, it can be difficult to extrapolate these effects to humans.

#### Epidemiologic Studies

In addition to studies in animals, a variety of other approaches are used to identify possible drug teratogenicity and to assess the relation between drug exposure and fetal outcome. The first accounts of adverse fetal outcomes after exposure to a marketed drug are usually published in the form of case reports. These reports can be either very useful or useless in establishing teratogenic risk on the basis of relatively simple statistical considerations. If the drug in question is taken by relatively small numbers of women (e.g., isotretinoin<sup>30</sup>) or causes a rare malformation (e.g., ear agenesis<sup>81</sup>), then a small number of cases can establish a strong association. Warfarin,<sup>9</sup> diethylstilbestrol,<sup>82</sup> and isotretinoin<sup>83</sup> were originally identified as human teratogens on the basis of case reports. If, on the other hand, the drug is taken by many pregnant women (e.g., Bendectin), a small number of case reports of abnormalities may simply reflect the spontaneous occurrence of malformations in the general population, which ranges from 1 to 5 percent, unless there is a characteristic pattern of malformations (as, for example, with alcohol or thalidomide). To date, prenatal exposure to many of the known human teratogens has been associated with characteristic patterns of malformations, and this has become an important tenet in establishing teratogenicity.

Epidemiologic studies are typically designed to determine whether mothers who took a specific drug during pregnancy have a larger number of malformed children than mothers who did not (cohort studies) or whether mothers of children with a specific malformation took the drug more often than mothers of children without the malformation (case-control studies).

With the international development of teratology-information services,<sup>84</sup> a new source of data for prospective observational research has emerged. Pregnant women taking prescription or over-the-counter drugs voluntarily call these centers for risk-assessment counseling, usually during the first trimester. Since the exposure data are recorded prospectively, the probability of recall bias is reduced, and follow-up of exposed pregnancies can extend well beyond parturition. Collaboration among these services can yield the large samples needed to study rare events more effectively.<sup>53,61,85</sup>

Drug manufacturers may perform postmarketing cohort studies of prospectively reported exposures.

**TABLE 3. TERATOGENIC EFFECTS OF DRUGS IN ANIMALS AND HUMANS.\***

DRUG	EFFECTS IN ANIMALS	EFFECTS IN HUMANS
Angiotensin-converting-enzyme inhibitors	Stillbirths and increased fetal loss in sheep and rabbits <sup>37</sup>	Prolonged renal failure and hypotension in the newborn, decreased skull ossification, hypocalvaria, and renal tubular dysgenesis <sup>38</sup>
Carbamazepine	Cleft palate, dilated cerebral ventricles, and growth retardation in mice <sup>39</sup>	Neural-tube defects <sup>40</sup>
Cocaine	Dose-dependent decrease in uterine blood flow, fetal hypoxemia, hypertension, and tachycardia in sheep <sup>41</sup> ; reduced fetal weight, fetal edema, and increased resorption in rats and mice <sup>42</sup>	Growth retardation involving weight, length, and head circumference <sup>43</sup> ; placental abruption <sup>44,45</sup> and uterine rupture
Ethanol	Microcephaly, growth deficiency, and limb anomalies in dogs, chickens, and mice <sup>46-48</sup>	Fetal alcohol syndrome: prenatal and postnatal growth deficiency, CNS anomalies (microcephaly, behavioral abnormalities, and mental retardation), characteristic pattern of facial features (short palpebral fissures, hypoplastic philtrum, and flattened maxilla), and major organ-system malformations <sup>49</sup> ; with age, facial features may become less distinctive, but short stature, microcephaly, and behavioral abnormalities persist <sup>50</sup>
Isotretinoin	CNS, head, limb, and cardiovascular defects in rats and rabbits <sup>29</sup>	Retinoid embryopathy resulting in some or all of the following abnormalities <sup>50</sup> : CNS defects (hydrocephalus, optic-nerve blindness, retinal defects, microphthalmia, posterior fossa defects, and cortical and cerebellar defects); craniofacial defects (microtia or anotia, low-set ears, hypertelorism, depressed nasal bridge, microcephaly, micrognathia, and agenesis or stenosis of external ear canals); cardiovascular defects (transposition of great vessels, tetralogy of Fallot, and ventricular or atrial septal defects); thymic defects (ectopia and hypoplasia or aplasia); and miscellaneous defects (limb reduction, decreased muscle tone, spontaneous abortion, and behavioral abnormalities)
Lithium	Heart defects in rats <sup>51</sup>	Ebstein's anomaly and other heart defects <sup>52,53</sup>
Methyl mercury	CNS abnormalities in rats <sup>54</sup> ; growth retardation, motor disturbances, microencephaly, and brain lesions in rhesus monkeys <sup>55</sup>	Fetal Minamata disease: diffuse neuronal disintegration with gliosis, cerebral palsy, microcephaly, strabismus, blindness, speech disorders, motor impairment, abnormal reflexes, and mental retardation <sup>56</sup>
Phenytoin	Cleft palate, micromelia, renal defects, and hydrocephalus in rabbits, mice, and rats <sup>57-59</sup>	Fetal hydantoin syndrome <sup>60</sup> : prenatal and postnatal growth deficiency, motor or mental deficiency, short nose with broad nasal bridge, microcephaly, hypertelorism, strabismus, epicanthus, wide fontanelles, low-set or abnormally formed ears, positional deformities of limbs, hypoplasia of nails and distal phalanges, hypospadias, hernia, webbed neck, low hairline, impaired neurodevelopment and low performance scores on tests of intelligence <sup>61</sup>
Thalidomide†	Limb-shortening defects in rabbits (most sensitive species) <sup>62</sup>	Limb-shortening defects, <sup>63</sup> loss of hearing, abducens paralysis, facial paralysis, anotia, microtia, renal malformations, congenital heart disease
Valproic acid	Exencephaly in hamsters and mice <sup>64,65</sup>	Neural-tube defects <sup>66,67</sup>
Warfarin†	Maxillofacial hypoplasia and skeletal anomalies in rats <sup>68</sup>	Fetal warfarin syndrome: skeletal defects (nasal hypoplasia and stippled epiphyses), limb hypoplasia (particularly in distal digits), low birth weight (<10th percentile), hearing loss, and ophthalmic anomalies <sup>69</sup> ; CNS defects with exposure after first trimester; dorsal midline dysplasia (agenesis of corpus callosum and Dandy-Walker malformations) or ventral midline dysplasia (optic atrophy) <sup>6</sup>

\*CNS denotes central nervous system.

†Initial studies in animals failed to show teratogenicity; hence, documentation in humans preceded that in animals.

Such studies were useful in establishing the safety and risk of Bendectin, isotretinoin, fluoxetine, and acyclovir.<sup>30,86</sup>

Because most studies of teratogenic risk are limited in size, meta-analyses of studies of similar design are becoming more frequent. A detailed, stepwise methodologic approach to meta-analysis of teratologic studies has been described.<sup>24</sup> The appropriate use of this approach depends to a large extent on establishing sound a priori criteria for methodologic quality and ensuring the inclusion of data from all available studies, in order to obviate any publication bias against negative results.

Long-term studies are increasingly important, because it is becoming clear that the long-term effects of teratogenic drugs on neurobehavioral develop-

ment can have a more devastating effect on children and their families than structural anomalies. To date, several drugs have been shown to affect brain development, including carbamazepine, isotretinoin, phenytoin, valproic acid, and warfarin (Table 1). Carbamazepine and valproic acid may cause cognitive brain dysfunction as part of the neural-tube defects they induce. Originally, isotretinoin was found to cause structural abnormalities that affected brain development, but recent studies have suggested that even phenotypically normal children may have abnormal neurodevelopment.<sup>87</sup> Warfarin was initially associated with chondrodysplasia punctata and mental retardation and has subsequently been found to cause the Dandy-Walker brain malformation in an estimated 1 to 2 percent of exposed fetuses.<sup>6,69</sup>

### Common Methodologic Issues

No single approach can definitively establish the safety or risk of drugs, because of several underlying difficulties.

#### Sample Size

Most congenital malformations occur rarely, and many teratogens, even when known to be associated with an increased risk of a given malformation, do not affect the great majority of exposed fetuses. In fact, very few drugs increase the total malformation rate by a factor of more than two (isotretinoin and thalidomide are two such drugs). If, for example, the risk of major malformations in a given population is 3 percent, then at least 220 pregnancies with the specific exposure and a similar number of control pregnancies will be required to show a risk that is increased by a factor of 2.5, with a power of 80 percent.

#### Effect of Maternal Diseases

Apart from drug therapy, many medical conditions themselves increase fetal risks. For example, pregnant women with hypertension or cancer are more likely to have infants with intrauterine growth retardation, and pregnant women with epilepsy or diabetes mellitus are more likely to have infants with malformations.<sup>88</sup> Therefore, any attempt to establish the role of fetal exposure to drugs must also address the contributing and confounding risk of the underlying maternal illness.

#### Recall Bias in Retrospective Studies

There is ample evidence of partial memory and bias in the way women recall the drugs they took during pregnancy. For example, women treated with a prescribed drug for a chronic illness tend to recall their treatment better than women who took an over-the-counter drug.<sup>89</sup> Women who have given birth to malformed children may be more likely to remember the course of their pregnancies, in the effort to understand what went wrong, than women who have given birth to healthy children, thus giving rise to false positive associations. The initial suggestions that benzodiazepines, spermicides, and Bectectin, for example, were teratogenic were based on retrospective case-control studies subsequently refuted by other, larger studies (Table 2).

With improved epidemiologic methods, the reliability of the case-control design has improved. For example, recruiting mothers of infants with a different major malformation as controls may eliminate or at least reduce the problem of differential maternal recall. In a recent study, this approach was used to document the effect of the mothers' knowledge of the study hypothesis (that folic acid deficiency causes spina bifida) on the information they reported.<sup>90</sup>

### Nonrandomized Observational Studies

With prospective observational studies, the treatment decisions have not been made by the investigators collecting the data. As a result, the indications for treatment and concurrent exposures are not standardized. Therefore, in comparisons of treated and untreated pregnant women or pregnant women who received two different drugs, preexisting confounding factors are not randomly distributed between the two groups. For example, in comparing the outcome of pregnancy in women who received carbamazepine and women who received phenytoin, one must address the issue of whether the two groups of women had the same type and severity of seizure disorder.

Observational studies of neurobehavioral development require longer follow-up than observational studies of other abnormalities, and interpretation of the results is often complicated by numerous confounding factors. Maternal and paternal IQ, socioeconomic status, and educational levels all affect cognitive development in children.<sup>91</sup> Any attempt to address the developmental effects of drugs without controlling for these factors is likely to be futile.

#### Voluntary Reporting

The information received by drug manufacturers is often a mix of prospective and retrospective case reports. The quality of the information about exposure is usually poor, and outcome data are sparse because of high rates of loss to follow-up. Most important, women and health professionals who contact manufacturers are likely to report adverse fetal outcomes, not uneventful ones. For example, the pivotal study that described retinoid embryopathy contained two parts: prospectively collected data from a study cohort, with a malformation rate of 36 percent, and data from voluntary retrospective reporting to the manufacturer, with a malformation rate of 80 percent.<sup>30</sup>

#### Meta-Analyses

A common concern regarding the use of meta-analysis is the inevitable combination of data from studies that are not equivalent in terms of quality and methods. In addition, there is the concern that negative studies (i.e., those that do not reject the null hypothesis) are less likely to be published than positive studies and that an overall positive association may therefore merely reflect unbalanced reporting.

### COUNSELING WOMEN ABOUT TERATOGENIC RISKS

In one study, women exposed to nonteratogenic drugs who sought counseling estimated, on average, that they had a 25 percent risk of major malformations, which is in the range of the teratogenic risk associated with thalidomide.<sup>2</sup> After counseling, this es-

imate was substantially reduced, thereby preventing numerous terminations of otherwise wanted pregnancies.<sup>2,3</sup> The same women correctly estimated the risk of major malformations in the general population (5 percent), indicating that the high risk they assigned to their own pregnancies was not due to a misunderstanding of the concept of base-line risk.

What are the sources of this misperception? Numerous lay publications misinform women by assigning risks to drugs not known to be teratogenic in humans.<sup>2,3</sup> Women often report that their physicians have encouraged them to terminate otherwise wanted pregnancies just to be on the safe side, suggesting that many physicians are unfamiliar with the current literature on the safety of drugs taken during pregnancy.

Physicians counseling women who are pregnant or are planning a pregnancy should make sure that they understand clearly the nature and magnitude of a risk associated with a drug. Women's attitudes toward voluntary abortion differ. In addition, the same information about the nature and magnitude of a teratogenic risk may prompt different decisions by different women, according to the clinical situation and specific circumstances. For example, women with epilepsy that has been treated effectively with phenytoin since their childhood may be glad to hear that although the drug is teratogenic, the overall risk of malformations is not high.<sup>61</sup> In contrast, women who have been treated with phenytoin for a single grand mal seizure and who have normal children born before phenytoin was prescribed may find it unacceptable to continue an unplanned pregnancy after learning about the higher-than-normal risk of adverse effects.

During counseling, it is important to ensure that a woman understands the concept of base-line teratogenic risk and the fetal or perinatal risks, if any, associated with her medical condition. For example, a woman with manic depression treated with lithium in the first trimester will need to understand not only the slightly increased risk of fetal cardiac anomalies associated with the drug (less than 1 percent)<sup>53</sup> but also the increased genetic risk of manic depression in her child. The counselor should be sure to communicate the same information to the woman's physician so that she does not receive conflicting advice.

To receive up-to-date, evidence-based information on the safety and risk of drugs during pregnancy, physicians can consult a teratogen-information service. Table 4 lists the World Wide Web addresses and telephone numbers of services in the United States and Canada.

#### THE FDA CLASSIFICATION OF TERATOGENICITY

To guide physicians in the interpretation of the teratogenic risk associated with prescription drugs,

**TABLE 4.** SELECTED TERATOGEN-INFORMATION SERVICES.

##### Canada

Motherisk Program, Toronto  
(416) 813-6780  
World Wide Web address: <http://www.motherisk.org>

##### United States

Organization of Teratology Information Services  
(801) 328-2229 (for referral to nearest service)  
World Wide Web address: <http://orpheus.ucsd.edu/ctis/>  
California Teratogen Information Service  
(619) 543-2131  
(800) 532-3749 (only in California)  
District of Columbia Reproductive Toxicology Center  
(202) 293-5137  
Florida Teratogen Information Service  
(352) 392-3050  
(800) 392-3050 (only in Florida)  
Illinois Teratogen Information Service  
(312) 908-7441  
(800) 252-4847 (only in Illinois)  
Indiana Teratogen Information Service  
(317) 274-1071  
Massachusetts Teratogen Information Service  
(781) 466-8474  
(800) 322-5014 (only in Massachusetts)  
Nebraska Teratogen Project  
(402) 559-5071  
New York Teratogen Information Service  
(716) 874-4747 (ext. 477)  
(800) 724-2454 (ext. 270) (only in New York)  
Texas Teratogen Information Service  
(800) 733-4727  
Utah Pregnancy Riskline  
(801) 328-2229  
Vermont Pregnancy Risk Information  
(802) 658-4310  
(800) 531-9800 (only in Vermont)

the FDA has established a system that classifies drugs on the basis of data from humans and animals, ranging from class A drugs, which are designated as safe for use during pregnancy, to class X drugs, which are contraindicated during pregnancy because of proven teratogenicity. This system has resulted in ambiguous statements that may be difficult to interpret and use for counseling and that can cause anxiety among women. In addition, the classification is often not changed when new data become available. For example, until recently, combined oral contraceptives were classified as class X drugs. Yet meta-analyses revealed that these combinations of estrogen and progestin were not associated with an increased risk of major malformations, in general,<sup>15</sup> or genitourinary malformations, in particular.<sup>16</sup> Each year, thousands of women become pregnant while taking these contraceptive hormones because of non-compliance or less-than-perfect efficacy, and their fetuses are exposed to the drugs during embryogenesis. In a similar fashion, tricyclic antidepressant

drugs are classified as D (“positive evidence of human fetal risk”), even though no such evidence exists and the available data suggest that these drugs are safe.<sup>85</sup> The Teratology Society has proposed that the FDA abandon the current classification system in favor of more meaningful, evidence-based, narrative statements.<sup>92</sup> At an FDA hearing held on September 15, 1997, this proposal received public support. Other countries (e.g., Sweden, Australia, the Netherlands, Switzerland, and Denmark) have different classification systems, although all are based on a hierarchy of estimated fetal risk.

**DRUGS OF CHOICE IN PREGNANCY**

Many pregnant women require drug therapy because of pregnancy-induced conditions such as nausea and vomiting, chronic conditions diagnosed before pregnancy, or acute conditions (e.g., those that require surgical treatment with the use of anesthetic agents).

Several principles should guide the selection of therapy during pregnancy. Since fetal safety is a major concern, effective drugs that have been in use for long periods are preferable to newer alternatives. Table 5 lists selected drugs considered to be safe on the

**TABLE 5.** SELECTED DRUGS THAT CAN BE USED SAFELY DURING PREGNANCY, ACCORDING TO CONDITION.\*

CONDITION	DRUGS OF CHOICE	ALTERNATIVE DRUGS	COMMENTS
Acne	Topical: erythromycin, clindamycin, benzoyl peroxide	Systemic: erythromycin, topical tretinoin (vitamin A acid)	Isotretinoin is contraindicated
Allergic rhinitis	Topical: glucocorticoids, cromolyn, decongestants, xylometazoline, oxymetazoline, naphazoline, phenylephrine; systemic: diphenhydramine, dimenhydrinate, tripeleennamine, astemizole		
Constipation	Docusate sodium, calcium, glycerin, sorbitol, lactulose, mineral oil, magnesium hydroxide	Bisacodyl, phenolphthalein	
Cough	Diphenhydramine, codeine, dextromethorphan		
Depression	Tricyclic antidepressant drugs, fluoxetine	Lithium	When lithium is used in first trimester, fetal echocardiography and ultrasonography are recommended because of small risk of cardiovascular defects
Diabetes	Insulin (human)	Insulin (beef or pork)	Hypoglycemic drugs should be avoided
Headache	Acetaminophen	Aspirin and nonsteroidal antiinflammatory drugs, benzodiazepines	Aspirin and nonsteroidal antiinflammatory drugs should be avoided in third trimester
Tension	Acetaminophen, codeine, dimenhydrinate	$\beta$ -adrenergic-receptor antagonists and tricyclic antidepressant drugs (for prophylaxis)	Limited experience with ergotamine has not revealed evidence of teratogenicity, but there is concern about potent vasoconstriction and uterine contraction
Migraine	Acetaminophen, codeine, dimenhydrinate		
Hypertension	Labetalol, methyldopa	$\beta$ -adrenergic-receptor antagonists, prazosin, hydralazine	Angiotensin-converting-enzyme inhibitors should be avoided because of risk of severe neonatal renal insufficiency
Hyperthyroidism	Propylthiouracil, methimazole	$\beta$ -adrenergic-receptor antagonists (for symptoms)	Surgery may be required; radioactive iodine should be avoided
Mania (and bipolar affective disorder)	Lithium, chlorpromazine, haloperidol	For depressive episodes: tricyclic antidepressant drugs, fluoxetine, valproic acid	If lithium is used in first trimester, fetal echocardiography and ultrasonography are recommended because of small risk of cardiac anomalies; valproic acid may be given after neural-tube closure is complete
Nausea, vomiting, motion sickness	Diclectin (doxylamine plus pyridoxine)	Chlorpromazine, metoclopramide (in third trimester), diphenhydramine, dimenhydrinate, meclizine, cyclizine	
Peptic ulcer disease	Antacids, magnesium hydroxide, aluminum hydroxide, calcium carbonate, ranitidine	Sucralfate, bismuth subsalicylate	
Pruritus	Topical: moisturizing creams or lotions, aluminum acetate, zinc oxide cream or ointment, calamine lotion, glucocorticoids; systemic: hydroxyzine, diphenhydramine, glucocorticoids, astemizole	Topical: local anesthetics	
Thrombophlebitis, deep-vein thrombosis	Heparin, antifibrinolytic drugs, streptokinase		Streptokinase is associated with a risk of bleeding; warfarin should be avoided

\*Data are from Smith et al.<sup>93</sup>

basis of either single large cohort studies or meta-analyses of several studies. Newer drugs may be more specific or have fewer adverse effects in adults, but their safety for fetuses is less likely to be known. For example, although acetaminophen with or without codeine may not be effective in many patients with migraine, it is widely used during pregnancy. Other, more potent antimigraine drugs are either too new (e.g., sumatriptan) or have known reproductive risks (e.g., ergotamine alkaloids that cause uterine contraction).

To minimize the fetal risk, drug doses at the lower end of the therapeutic range should be prescribed during pregnancy. However, because of increased body weight and more rapid clearance of many drugs (e.g., lithium, digoxin, and phenytoin) during late pregnancy, some women may need higher-than-normal doses.<sup>94</sup>

Pregnant women should be discouraged from taking over-the-counter drugs, and such drugs should not be taken without counseling, since many factors, including the stage of pregnancy, can influence the risk to the fetus. For example, a nonsteroidal antiinflammatory drug may be taken safely for pain during the first trimester of pregnancy, but there is increasing evidence that some nonsteroidal antiinflammatory drugs constrict or even close the fetal ductus arteriosus during late pregnancy.<sup>95</sup>

### CONCLUSIONS

In addition to the risk associated with fetal exposure to teratogenic drugs, there is a risk associated with misinformation about the teratogenicity of drugs, which can lead to unnecessary abortions or the avoidance of needed therapy. The medical community and drug manufacturers should make a concerted effort to protect women and their unborn babies from both risks.

Supported by grants from the Medical Research Council of Canada, the National Health and Welfare Research Program, the Medical Research Council-Pharmaceutical Manufacturers Association of Canada Program, Physicians Services, Novartis, Roche Canada, Duchesnay, and the Motherisk Research Fund.

### REFERENCES

- Better news on population. *Lancet* 1992;339:1600.
- Koren G, Bologna M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. *Am J Obstet Gynecol* 1989;160:1190-4.
- Koren G, Pastuszak A. Prevention of unnecessary pregnancy termination by counselling women on drug, chemical, and radiation exposure during the first trimester. *Teratology* 1990;41:657-61.
- Newton ER, ed. Medical problems in pregnancy. *Med Clin North Am* 1989;73:517-752.
- Moore KL. The developing human: clinically oriented embryology. 4th ed. Philadelphia: W.B. Saunders, 1988:131.
- Schardein JL. Chemically induced birth defects. 2nd ed. rev. New York: Marcel Dekker, 1993.
- Lenz W, Knapp K. Die Thalidomid-Embryopathie. *Dtsch Med Wochenschr* 1962;87:1232-42.
- Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 4th ed. Baltimore: Williams & Wilkins, 1994.
- Saxen I. Associations between oral clefts and drugs taken during pregnancy. *Int J Epidemiol* 1975;4:37-44.
- Rosenberg L, Mitchell AA, Parsells JL, Pashayan H, Luvik C, Shapiro S. Lack of relation of oral clefts to diazepam use during pregnancy. *N Engl J Med* 1983;309:1282-5.
- Shiono PH, Mills JL. Oral clefts and diazepam use during pregnancy. *N Engl J Med* 1984;311:919-20.
- Czeizel A. Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. *Reprod Toxicol* 1987;1:183-8.
- Nora JJ, Nora AH, Blu J, et al. Exogenous progestogen and estrogen implicated in birth defects. *JAMA* 1978;240:837-43.
- Schardein JL. Congenital abnormalities and hormones during pregnancy: a clinical review. *Teratology* 1980;22:251-70.
- Bracken MB. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. *Obstet Gynecol* 1990;76:552-7.
- Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. *Obstet Gynecol* 1995;85:141-9.
- Jick H, Walker AM, Rothman KJ, et al. Vaginal spermicides and congenital disorders. *JAMA* 1981;245:1329-32.
- Einarson TR, Koren G, Mattice D, Schechter-Tsafirri O. Maternal spermicide use and adverse reproductive outcome: a meta-analysis. *Am J Obstet Gynecol* 1990;162:655-60.
- Walker BE. Induction of cleft palate in rats with antiinflammatory drugs. *Teratology* 1971;4:39-42.
- Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. *N Engl J Med* 1989;321:1639-42.
- Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Aspirin and congenital malformations. *Lancet* 1976;1:1373-5.
- Dickson JH. Congenital deformities associated with Bendectin. *Can Med Assoc J* 1977;117:721.
- Donnai D, Harris R. Unusual fetal malformations after antiemetics in pregnancy. *BMJ* 1978;1:691-2.
- Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. *Drug Intell Clin Pharm* 1988;22:813-24.
- McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects. I. A meta-analysis of the epidemiologic studies. *Teratology* 1994;50:27-37.
- Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. *Can J Public Health* 1995;68:66-70.
- Ornstein M, Einarson A, Koren G. Bendectin/Diclectin for morning sickness: a Canadian follow-up of an American tragedy. *Reprod Toxicol* 1995;9:1-6.
- Mazzotta P, Magee L, Koren G. Therapeutic abortions due to morning sickness: unacceptable combination. *Can Fam Physician* 1997;43:1055-7.
- Fantel AG, Shepard TH, Newell-Morris LL, Moffett BC. Teratogenic effects of retinoic acid in pigtail monkeys (*Macaca nemestrina*). I. General features. *Teratology* 1977;15:65-71.
- Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. *N Engl J Med* 1985;313:837-41.
- A nation of illiterates. *US News and World Report*. May 17, 1982:1.
- Pastuszak AL, Koren G, Rieder MJ. Use of the Retinoid Pregnancy Prevention Program in Canada: patterns of contraception use in women treated with isotretinoin and etretinate. *Reprod Toxicol* 1994;8:63-8.
- Koren G. The children of neverland: the silent human disaster. Toronto: Kid In Us, 1997.
- Jones GR. Thalidomide: 35 years on and still deforming. *Lancet* 1994;343:1041.
- Polaneczky M, Slap G, Forke C, Rappaport A, Sondheimer S. The use of levonorgestrel implants (Norplant) for contraception in adolescent mothers. *N Engl J Med* 1994;331:1201-6.
- Glazier A. Emergency postcoital contraception. *N Engl J Med* 1997;337:1058-64.
- Pipkin FB, Turner SR, Symonds EM. Possible risk with captopril in pregnancy: some animal data. *Lancet* 1980;1:1256.
- Rosa FW, Bosco LA, Graham CF, et al. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. *Obstet Gynecol* 1989;74:371-4.
- Sullivan FM, McElhatton PR. A comparison of the teratogenic activity of the antiepileptic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, and primidone in mice. *Toxicol Appl Pharmacol* 1977;40:365-78.
- Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. *N Engl J Med* 1991;324:674-7.
- Wood JR Jr, Plessinger MA, Clark KE. Effect of cocaine on uterine blood flow and fetal oxygenation. *JAMA* 1987;257:957-61.
- Fantel AG, Macphail BJ. The teratogenicity of cocaine. *Teratology* 1982;26:17-9.

43. Weathers WT, Crane MM, Sauvain KJ, Blackhurst DW. Cocaine use in women from a defined population: prevalence at delivery and effects on growth in infants. *Pediatrics* 1993;91:350-4.
44. Lutiger B, Graham K, Einarson TR, Koren G. Relationship between gestational cocaine use and pregnancy outcome: a meta-analysis. *Teratology* 1991;44:405-14.
45. Chasnoff IJ. Cocaine, pregnancy, and the growing child. *Curr Probl Pediatr* 1992;22:302-21.
46. Ellis FW, Pick JR. An animal model of the fetal alcohol syndrome in beagles. *Alcohol Clin Exp Res* 1980;4:123-34.
47. Shoemaker WJ, Koda LY, Shoemaker CA, Bloom FE. Ethanol effects in chick embryos: cerebellar Purkinje neurons. *Neurobehav Toxicol* 1980;2:239-42.
48. Sulik KK, Johnston MC, Webb MA. Fetal alcohol syndrome: embryogenesis in a mouse model. *Science* 1981;214:936-8.
49. Clarren SK. Recognition of fetal alcohol syndrome. *JAMA* 1981;245:2436-9.
50. Streissguth AP, Aase JM, Clarren SK, Randels SP, LaDue RA, Smith DF. Fetal alcohol syndrome in adolescents and adults. *JAMA* 1991;265:1961-7.
51. Wilby OK, Tesh SA, Ross FW, Tesh JM. Effects of lithium on development in vitro and in vivo in the rat. *Teratology* 1987;35:69. abstract.
52. Nora JJ, Nora AH, Toews WH. Lithium, Ebstein's anomaly, and other congenital heart defects. *Lancet* 1974;2:594-5.
53. Jacobson SJ, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. *Lancet* 1992;339:530-3.
54. Tatetsu M. Experimental manifestation of "congenital Minamata disease." *Psychiatr Neurol Jpn* 1968;70:162.
55. Dougherty WJ, Coulston F, Golberg L. Toxicity of methylmercury in pregnant rhesus monkeys. *Toxicol Appl Pharmacol* 1974;29:138. abstract.
56. Matsumoto H, Koya G, Takeuchi T. Fetal Minamata disease: a neuropathological study of two cases of intrauterine intoxication by a methyl mercury compound. *J Neuropathol Exp Neurol* 1965;24:563-74.
57. McClain RM, Langhoff L. Teratogenicity of diphenylhydantoin in New Zealand white rabbits. *Toxicol Appl Pharmacol* 1979;48:A32. abstract.
58. Finnell RH. Phenytoin-induced teratogenesis: a mouse model. *Science* 1981;211:483-4.
59. Harbison RD. Studies on the mechanism of teratogenic action and neonatal pharmacology of diphenylhydantoin. (Ph.D. thesis. Iowa City: State University of Iowa, 1969.)
60. Hanson JW, Smith DW. The fetal hydantoin syndrome. *J Pediatr* 1975;87:285-90.
61. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. *JAMA* 1994;271:767-70.
62. Fratta ID, Sigg EB, Maiorana K. Teratogenic effects of thalidomide in rabbits, rats, hamsters, and mice. *Toxicol Appl Pharmacol* 1965;7:268-86.
63. McBride WG. Thalidomide and congenital abnormalities. *Lancet* 1961;2:1358.
64. Nau H. Species differences in pharmacokinetics and drug teratogenesis. *Environ Health Perspect* 1986;70:113-29.
65. Fimmel RH, Bennett GD, Karras SB, Mohl VK. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. *Teratology* 1988;38:313-20.
66. Jager-Roman E, Deichi A, Jakob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. *J Pediatr* 1986;108:997-1004.
67. Lammer EJ, Sever LE, Oakley GP Jr. Teratogen update: valproic acid. *Teratology* 1987;35:465-73.
68. Howe AM, Webster WS. The warfarin embryopathy: a rat model showing maxillofacial hypoplasia and other skeletal disturbances. *Teratology* 1992;46:379-90.
69. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anti-coagulation during pregnancy. *Am J Med* 1980;68:122-40.
70. Baxter H, Fraser FC. The production of congenital defects in the offspring of female mice treated with cortisone. *McGill Med J* 1950;19:245-9.
71. Fainstat T. Cortisone-induced congenital cleft palate in rabbits. *Endocrinology* 1954;55:502-8.
72. Buresh JJ, Urban TJ. The teratogenic effect of the steroid nucleus in the rat. *J Dent Res* 1970;43:548-54.
73. Wilson JG, Fradkin R, Schumacher HJ. Influence of drug pretreatment on the effectiveness of known teratogenic agents. *Teratology* 1970;3:210-1. abstract.
74. Pinsky L, DiGeorge AM. Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. *Science* 1965;147:402-3.
75. Fraser FC, Sajoo A. Teratogenic potential of corticosteroids in humans. *Teratology* 1995;51:45-6.
76. Shepard TH. Catalog of teratogenic agents. 7th ed. Baltimore: Johns Hopkins University Press, 1994.
77. Miller RP, Becker BA. Teratogenicity of oral diazepam and diphenylhydantoin in mice. *Toxicol Appl Pharmacol* 1975;32:53-61.
78. Klein KL, Scott WJ, Wilson JG. Aspirin-induced teratogenesis: a unique pattern of cell death and subsequent polydactyly in the rat. *J Exp Zool* 1981;216:107-12.
79. Wilson JG, Ritter EJ, Scott WJ, Fradkin R. Comparative distribution and embryotoxicity of acetylsalicylic acid in pregnant rats and rhesus monkeys. *Toxicol Appl Pharmacol* 1977;41:67-78.
80. Beall JR, Klein MF. Enhancement of aspirin-induced teratogenicity by food restriction in rats. *Toxicol Appl Pharmacol* 1977;39:489-95.
81. Mastroiacovo P, Corchia C, Botto LD, Lanni R, Zampino G, Fusco D. Epidemiology and genetics of microtia-anotia: a registry based study on over one million births. *J Med Genet* 1995;52:453-7.
82. Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence: a report of 7 cases including 6 clear-cell carcinomas. *Cancer* 1970;25:745-57.
83. Rosa FW. Teratogenicity of isotretinoin. *Lancet* 1983;2:513.
84. Koren G, Pastuszak A. Teratogen information services. In: Koren G, ed. *Maternal-fetal toxicology: a clinician's guide*. 2nd ed. rev. New York: Marcel Dekker, 1994:683-705.
85. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine. *JAMA* 1993;269:2246-8.
86. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. *Obstet Gynecol* 1997;89:713-8.
87. Adams J. Neural and behavioral pathology following prenatal exposure to retinoids. In: Koren G, ed. *Retinoids in clinical practice: the risk-benefit ratio*. New York: Marcel Dekker, 1993:111-28.
88. Gonen R, Shilalukey K, Magee L, Koren G, Shime J. Maternal disorders leading to increased reproductive risk. In: Koren G, ed. *Maternal-fetal toxicology: a clinician's guide*. 2nd ed. rev. New York: Marcel Dekker, 1994:641-82.
89. Feldman Y, Koren G, Mattice K, Shear H, Pellegrini E, MacLeod SM. Determinants of recall and recall bias in studying drug and chemical exposure in pregnancy. *Teratology* 1989;40:37-45.
90. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. *JAMA* 1993;269:1257-61.
91. McCall RB. The development of intellectual functioning in infancy and the prediction of later I.Q. In: Osofsky JD, ed. *Handbook of infant development*. New York: John Wiley, 1979:707-41.
92. Teratology Society Public Affairs Committee. FDA classification of drugs for teratogenic risk. *Teratology* 1994;49:446-7.
93. Smith J, Taddio A, Koren G. Drugs of choice for pregnant women. In: Koren G, ed. *Maternal-fetal toxicology: a clinician's guide*. 2nd ed. rev. New York: Marcel Dekker, 1994:115-28.
94. Loebstein R, Lalkin A, Koren G. Pregnancy induced pharmacokinetic changes and their clinical relevance. *Clin Pharmacokinet* 1997;33:328-43.
95. Theis JGW. Acetylsalicylic acid (ASA) and nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy: are they safe? *Can Fam Physician* 1996;42:2347-9.